Treatment of Posttransplantation Recurrent Glomerulonephritis: IgA Nephropathy, Membranous Nephropathy, Membranoproliferative Glomerulonephritis / 대한이식학회지

ABSTRACT

As the clinical outcomes improve in kidney transplantation, largely because of the prevention of loss due to acute rejection, the incidence of allograft loss due to recurrent glomerulonephritis have become more important. Actually recurrent glomerulonephritis is the third most common cause of graft failure, ranking only behind immunologic rejection and death with a functioning graft. Preventive and therapeutic treatment strategies are necessary for those patients at risk. Current newer immunosuppressive protocols over the past 10 years have not affected the rate of disease recurrence or graft loss. In a certain recurrent glomerulitis, for example membranous nephropathy, there is emerging evidence that rituximab may be efficacious; however, larger clinical trials are warranted.